Marc D. Normandin
YOU?
Author Swipe
View article: Deformable Image Registration for Assessing Time-Course Effect of Proton Beam in the Heart in the Presence of Large Anatomical Variations
Deformable Image Registration for Assessing Time-Course Effect of Proton Beam in the Heart in the Presence of Large Anatomical Variations Open
View article: A Large Animal Study of a Novel Cardiac-Ultrasound Image Guidance for Cardio-Respiratory-Gated Radiation Ablation to Ventricular Tachycardia Targets Using Proton Therapy
A Large Animal Study of a Novel Cardiac-Ultrasound Image Guidance for Cardio-Respiratory-Gated Radiation Ablation to Ventricular Tachycardia Targets Using Proton Therapy Open
View article: In vivo 3D myocardial membrane potential mapping in humans using PET/MRI
In vivo 3D myocardial membrane potential mapping in humans using PET/MRI Open
Background The mitochondrial membrane potential is a key biophysical parameter of mitochondrial function , which can be useful for the diagnosis and treatment monitoring of various cardiac diseases. We present a non-invasive PET/MR imaging…
View article: Quantitative Measurement of Tau Burden in a Dual-Time-Window Dynamic PET Imaging Protocol with [<sup>18</sup>F]MK6240
Quantitative Measurement of Tau Burden in a Dual-Time-Window Dynamic PET Imaging Protocol with [<sup>18</sup>F]MK6240 Open
This study aimed to test and validate a dual-time-window (DTW) protocol for 6-(fluoro-18F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine ([18F]MK6240) dynamic PET imaging in experimental datasets acq…
View article: Deciphering the effects of radiopharmaceutical therapy in the tumor microenvironment of prostate cancer: an in-silico exploration with spatial transcriptomics
Deciphering the effects of radiopharmaceutical therapy in the tumor microenvironment of prostate cancer: an in-silico exploration with spatial transcriptomics Open
Radiopharmaceutical therapy (RPT) is an emerging prostate cancer treatment that delivers radiation to specific molecules within the tumor microenvironment (TME), causing DNA damage and cell death. Given TME heterogeneity, it's crucial to e…
View article: PET Mapping of Receptor Occupancy Using Joint Direct Parametric Reconstruction
PET Mapping of Receptor Occupancy Using Joint Direct Parametric Reconstruction Open
This work could potentially facilitate the evaluation of new drug candidates targeting the CNS.
View article: Free‐breathing <scp>3D</scp> cardiac extracellular volume (<scp>ECV</scp>) mapping using a linear tangent space alignment (<scp>LTSA</scp>) model
Free‐breathing <span>3D</span> cardiac extracellular volume (<span>ECV</span>) mapping using a linear tangent space alignment (<span>LTSA</span>) model Open
Purpose To develop a new method for free‐breathing 3D extracellular volume (ECV) mapping of the whole heart at 3 T. Methods A free‐breathing 3D cardiac ECV mapping method was developed at 3 T. T 1 mapping was performed before and after con…
View article: Radiosynthesis automation, non-human primate biodistribution and dosimetry of K+ channel tracer [11C]3MeO4AP
Radiosynthesis automation, non-human primate biodistribution and dosimetry of K+ channel tracer [11C]3MeO4AP Open
Background 4-Aminopyridine (4AP) is a medication for the symptomatic treatment of multiple sclerosis. Several 4AP-based PET tracers have been developed for imaging demyelination. In preclinical studies, [ 11 C]3MeO4AP has shown promise due…
View article: Head-to-head comparison of [18F]-Flortaucipir, [18F]-MK-6240 and [18F]-PI-2620 postmortem binding across the spectrum of neurodegenerative diseases
Head-to-head comparison of [18F]-Flortaucipir, [18F]-MK-6240 and [18F]-PI-2620 postmortem binding across the spectrum of neurodegenerative diseases Open
View article: Evaluation of <i>trans</i>- and <i>cis</i>-4-[<sup>18</sup>F]Fluorogabapentin for Brain PET Imaging
Evaluation of <i>trans</i>- and <i>cis</i>-4-[<sup>18</sup>F]Fluorogabapentin for Brain PET Imaging Open
Gabapentin, a selective ligand for the α2δ subunit of voltage-dependent calcium channels, is an anticonvulsant medication used in the treatment of neuropathic pain, epilepsy, and other neurological conditions. We recently described two rad…
View article: Short Timetable – Table of Content
Short Timetable – Table of Content Open
Development of a novel crucible free crystal growth
View article: Evaluation of<i>trans</i>- and<i>cis</i>-4-[<sup>18</sup>F]fluorogabapentin for brain PET imaging
Evaluation of<i>trans</i>- and<i>cis</i>-4-[<sup>18</sup>F]fluorogabapentin for brain PET imaging Open
Gabapentin, a selective ligand for the α2δ subunit of voltage-dependent calcium channels, is an anticonvulsant medication used in the treatment of neuropathic pain, epilepsy and other neurological conditions. We recently described two radi…
View article: TauPETGen: Text-Conditional Tau PET Image Synthesis Based on Latent Diffusion Models
TauPETGen: Text-Conditional Tau PET Image Synthesis Based on Latent Diffusion Models Open
In this work, we developed a novel text-guided image synthesis technique which could generate realistic tau PET images from textual descriptions and the subject's MR image. The generated tau PET images have the potential to be used in exam…
View article: Tau Positron Emission Tomography and Neurocognitive Function Among Former Professional American-Style Football Players
Tau Positron Emission Tomography and Neurocognitive Function Among Former Professional American-Style Football Players Open
American-style football (ASF) players experience repetitive head impacts that may result in chronic traumatic encephalopathy neuropathological change (CTE-NC). At present, a definitive diagnosis of CTE-NC requires the identification of loc…
View article: Impact of motion correction on [<sup>18</sup>F]-MK6240 tau PET imaging
Impact of motion correction on [<sup>18</sup>F]-MK6240 tau PET imaging Open
Objective . Positron emission tomography (PET) imaging of tau deposition using [ 18 F]-MK6240 often involves long acquisitions in older subjects, many of whom exhibit dementia symptoms. The resulting unavoidable head motion can greatly deg…
View article: Table S1 from [<sup>18</sup>F]Fluorocholine and [<sup>18</sup>F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM
Table S1 from [<sup>18</sup>F]Fluorocholine and [<sup>18</sup>F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM Open
Summary of FCH and FACE Imaging
View article: Table S1 from [<sup>18</sup>F]Fluorocholine and [<sup>18</sup>F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM
Table S1 from [<sup>18</sup>F]Fluorocholine and [<sup>18</sup>F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM Open
Summary of FCH and FACE Imaging
View article: Figure S4 from [<sup>18</sup>F]Fluorocholine and [<sup>18</sup>F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM
Figure S4 from [<sup>18</sup>F]Fluorocholine and [<sup>18</sup>F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM Open
[18F]FACE-PET of TSC2-deficient tumors after 72-hr exposure to vehicle control (a representative mouse).
View article: Data from [<sup>18</sup>F]Fluorocholine and [<sup>18</sup>F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM
Data from [<sup>18</sup>F]Fluorocholine and [<sup>18</sup>F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM Open
Purpose:Tuberous sclerosis complex (TSC) is an autosomal dominant disorder caused by inactivating mutations of the TSC1 or TSC2 gene, characterized by neurocognitive impairment and benign tumors of the brain, skin, heart, and…
View article: Figure S3 from [<sup>18</sup>F]Fluorocholine and [<sup>18</sup>F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM
Figure S3 from [<sup>18</sup>F]Fluorocholine and [<sup>18</sup>F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM Open
[18F]FCH and [18F]FACE-PET images of LAM patient renal angiomyolipoma-derived tumor xenografts.
View article: Figure S3 from [<sup>18</sup>F]Fluorocholine and [<sup>18</sup>F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM
Figure S3 from [<sup>18</sup>F]Fluorocholine and [<sup>18</sup>F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM Open
[18F]FCH and [18F]FACE-PET images of LAM patient renal angiomyolipoma-derived tumor xenografts.
View article: Figure S6 from [<sup>18</sup>F]Fluorocholine and [<sup>18</sup>F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM
Figure S6 from [<sup>18</sup>F]Fluorocholine and [<sup>18</sup>F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM Open
Increased mitochondrial acetate oxidation induced by treatment with rapamycin.
View article: Figure S2 from [<sup>18</sup>F]Fluorocholine and [<sup>18</sup>F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM
Figure S2 from [<sup>18</sup>F]Fluorocholine and [<sup>18</sup>F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM Open
[18F]FCH uptake in TSC2-deficient cells in vivo after 72-hr exposure to vehicle control (two representative mice).
View article: Figure S1 from [<sup>18</sup>F]Fluorocholine and [<sup>18</sup>F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM
Figure S1 from [<sup>18</sup>F]Fluorocholine and [<sup>18</sup>F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM Open
Suppression of [18F]FCH uptake by treatment with rapamycin in TSC2-deficient cells in vivo (representative mouse 2).
View article: Figure S4 from [<sup>18</sup>F]Fluorocholine and [<sup>18</sup>F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM
Figure S4 from [<sup>18</sup>F]Fluorocholine and [<sup>18</sup>F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM Open
[18F]FACE-PET of TSC2-deficient tumors after 72-hr exposure to vehicle control (a representative mouse).
View article: Figure S5 from [<sup>18</sup>F]Fluorocholine and [<sup>18</sup>F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM
Figure S5 from [<sup>18</sup>F]Fluorocholine and [<sup>18</sup>F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM Open
[18F]FACE-PET of TSC2-deficient tumors after 48-hr exposure to rapamycin or vehicle control.
View article: Figure S1 from [<sup>18</sup>F]Fluorocholine and [<sup>18</sup>F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM
Figure S1 from [<sup>18</sup>F]Fluorocholine and [<sup>18</sup>F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM Open
Suppression of [18F]FCH uptake by treatment with rapamycin in TSC2-deficient cells in vivo (representative mouse 2).
View article: Figure S2 from [<sup>18</sup>F]Fluorocholine and [<sup>18</sup>F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM
Figure S2 from [<sup>18</sup>F]Fluorocholine and [<sup>18</sup>F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM Open
[18F]FCH uptake in TSC2-deficient cells in vivo after 72-hr exposure to vehicle control (two representative mice).
View article: Figure S6 from [<sup>18</sup>F]Fluorocholine and [<sup>18</sup>F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM
Figure S6 from [<sup>18</sup>F]Fluorocholine and [<sup>18</sup>F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM Open
Increased mitochondrial acetate oxidation induced by treatment with rapamycin.
View article: Supplementary text from [<sup>18</sup>F]Fluorocholine and [<sup>18</sup>F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM
Supplementary text from [<sup>18</sup>F]Fluorocholine and [<sup>18</sup>F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM Open
Supplementary Methods and Figure Legends